IsomAb is a pre-clinical company developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by the company Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.
The mechanism of action of ISM-001 is unique and would be the only treatment to target a key pathway and reduce harmful serum levels of VEGF165b. ISM-001 would provide an unparalleled approach to treatment of patients including those with Type II diabetes mellitus and peripheral vascular disease at risk of amputation.
See more at www.isomab.bio